First Wave BioPharma Stock Jumps On Niclosamide's Favorable Safety Profile In COVID-19 Related GI Infections

by Vandana Singh, Benzinga Editor

November 30, 2021 8:33 AM | 1 min read |

The independent data monitoring committee (DMC) has recommended First Wave BioPharma Inc FWBI to continue enrollment in Part 2 of the RESERVOIR Phase 2 trial evaluating FW-COV for COVID-19-related gastrointestinal (GI) infections.
FW-COV is a proprietary, oral tablet formulation of micronized niclosamide developed to remove SARS-CoV-2 from the GI tract.
The DMC recommendation was based on the safety data collected from the first 25 patients enrolled in Part 2 of the RESERVOIR trial.
The review of the data uncovered no safety issues. Part 2 of the study will enroll up to 150 patients.
Price Action: FWBI shares are up 38.6% at $2.62 during the premarket session on the last check Tuesday.

Posted In: Biotech Long Ideas News Penny Stocks Health Care Movers Trading Ideas General Briefs COVID-19 Coronavirus Phase 2 Trial why it's moving

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.